Pfizer Inc. (NYSE:PFE) discontinued the Phase IIb STRIVE trial of PF-06290510 to prevent postoperative invasive Staphylococcus aureus infections in patients
Pfizer Inc. (NYSE:PFE) discontinued the Phase IIb STRIVE trial of PF-06290510 to prevent postoperative invasive Staphylococcus aureus infections in patients